Kivu Bioscience是一家癌症靶向药物研发商，该公司专有的linker-payload技术可提供更高的安全性和有效性，最大限度地减少脱靶效应，从而改善患者预后。近日，Kivu Bioscience宣布完成9200万美元A轮融资，由Novo Holdings领投，Gimv、Red Tree Venture ...

Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates ...

Congo reported fewer than 100 mpox cases last week, down from nearly 400 in July but infections have risen in Burundi and ...

In a report published on Monday, the World Health Organisation said that mpox cases in the South Kivu region of the DRC seem ...

Congolese radio journalist Yoshua Kambere Machozi was arrested by members of the rebel group M23 (23 March Movement) on 29 ...

Rwanda offers a fresh perspective for travellers, blending its natural beauty with a sense of community. From the shores of ...

Kamandi-Gite is situated approximately 130 kilometres from Goma City. Several reliable sources confirmed the presence of M23 ...

Rwanda and the Democratic Republic of Congo (DRC) launched a joint monitoring mechanism in a bid to tame a vicious cycle of ...

San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round ...

The World Health Organization reports that mpox cases are plateauing in Congo's South Kivu region, despite rising numbers in the rest of the country, Burundi, and Uganda. With fewer than 100 confirmed ...

Kivu Bioscience has closed a $92 million series A financing to advance its topoisomerase I inhibitor-based antibody-drug conjugate (ADC) pipeline into the clinic.

Some health officials say mpox cases in Congo appear to be “stabilizing.” It's a possible sign that the epidemic for which ...